WuXi Bi­o­log­ics’ li­cens­ing deals help off­set Biose­cure threat in the US

WuXi Bi­o­log­ics at­trib­uted a 32.5% in­crease in North Amer­i­can rev­enue last year to out-li­cens­ing deals with glob­al drug­mak­ers de­spite the “dy­nam­ic po­lit­i­cal en­vi­ron­ment” in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER